Product Description
a modified recombinant activated factor VII (FVIIa). In the single patient with haemophilia A who developed anti-BAY 86-6150 antibodies, results of T-cell epitope mapping indicated BAY 86-6150 was no more immunogenic than WT-FVIIa. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27501279/)
Mechanisms of Action: Eptacog Alfa Cleaver
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hemophilia A|Hemophilia B
Phase 1: Hemophilia B|Hemophilia A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
U1111-1133-2156 | P3 |
Completed |
Hemophilia B|Hemophilia A |
2014-03-01 |
|
MATCHBOX | P1 |
Completed |
Hemophilia B|Hemophilia A |
2009-12-01 |